Recent Updates
Recently added Catalysts

BriaCell Therapeutics Corp.

BCTX
OvervaluedBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$3.95
▲ +0.03 · +0.77%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BCTX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.6052W HIGH $14.68
Volume
2.04 K
Value Traded
312.45 K
Short % Float
9.12%
-2.97%Week
+7.99%1 Month
-0.51%3 Month
-8.41%6 Month
-99.26%5 Year
-99.99%All Time

Cash Data

Unlock BCTX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
34.36 M
EPS (TTM)
-3.53
P/E Ratio
-
Ent. Value
11.30 M
Total Shares
8.70 M
Float Shares
8.69 M
Insiders
0.15%
Institutions
14.08%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data presentation
Tumor-targeted checkpoint inhibitors
Cancer
Pre-clinicalBiologicsOncology
Unlock every BCTX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BCTX Catalyst Timeline

Dated clinical, regulatory and corporate events for BriaCell Therapeutics Corp.

Catalyst Timeline

Dated clinical, regulatory & corporate events for BriaCell Therapeutics Corp.

602Total events
6Upcoming
93Tier-1 (high impact)
2015 to 2027Coverage

Upcoming catalysts 2

T3Poster Presentation
Subscribe to view catalyst details
Bria-OTS™
T3Poster Presentation
Subscribe to view catalyst details

Event history 50

▲DSMB ReviewBria-IMT™Trial
DSMB issues seventh consecutive positive recommendation for Phase 3 Bria-ABC study of Bria-IMT plus CPI
metastatic breast cancersource ↗
▲Enrollment UpdateBria-IMT™Trial
Memorial Sloan Kettering Cancer Center joins Phase 3 Bria-ABC study and is now enrolling patients
metastatic breast cancersource ↗
▲DSMB ReviewBria-IMT™Trial
DSMB recommends continuation of Phase 3 study
metastatic breast cancersource ↗
▲Manufacturing MilestoneBria-MelCMC / Inspection
Bria-MEL+ achieves key genetic engineering milestone
melanomasource ↗
▲IND ClearanceBria-PROSIND
Bria-PROS+ receives FDA clearance to initiate clinical evaluation
prostate cancersource ↗
▲IND ClearanceBria-PROSIND
FDA clearance of IND for Bria-PROS+
prostate cancersource ↗
▲Enrollment MilestoneBria-IMT™Trial
First Canadian site opened for Phase 3 trial
metastatic breast cancersource ↗
▲DSMB ReviewBria-IMT™Trial
DSMB positive recommendation to continue Phase 3 study
metastatic breast cancersource ↗
▲Manufacturing MilestoneBria-IMT™CMC / Inspection
Manufacturing arrangement with FUJIFILM Biotechnologies California for Bria-IMT
metastatic breast cancersource ↗
●Quarterly UpdateBria-IMT™Corporate
Engaged Charles River Associates and Kaleio for commercial strategy and market access evaluation for Bria-IMT
metastatic breast cancersource ↗
Unlock the full BCTX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BCTX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-30Bria-IMT plus immune checkpoint inhibitor Phase 3 topline data readout Phase 3
Unlock 5 more BCTX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D26 / 100
Pipeline Score
$8M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Top 79%
Micro Cap
(rank 520 of 658)
Percentile Rank
BriaCell Therapeutics Corp. faces pipeline headwinds (26/100), with $327M risk-adjusted pipeline value, led by SV-BR-1-GM in Breast Cancer (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SV-BR-1-GM Monoclonal antibodyNCT03328026Breast CancerPhase 3 COMPLETED 440Mar 24, 2026
Unlock the BCTX pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BCTX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Bria-IMT
Fast Track
metastatic breast cancerPhase 32026-07-16positive Phase 2 survival dataRead MoreBriaCell Opens First Canadian Site · Sunnybrook · for Pivotal Phase 3 Trial in Metastatic Breast CancerRead More
Scroll for more · summaries link to the source press release
Unlock every BCTX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BCTX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Lustig MarcDirector, 10% OwnerBuy 902,935 902,935 held$0.00 05/14/2024
Unlock the full BCTX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in BCTX

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in BCTX for Q2 2026.
Unlock every fund holding BCTX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BCTX
Shares held by hedge funds each quarter, and who bought or sold.

BCTX Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock BCTX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BCTX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BCTX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BCTX ranks across every disease it competes in

Competitive Position is a premium feature
See how BCTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BCTX News

BCTX
Oct 6, 2026
BCTXConferences/Events
▲ +0.8%today

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BriaCell Therapeutics Corp. and its subsidiary BriaPro will present four abstracts at the SITC 2026 Annual Meeting in Phoenix, AZ. The presentations will cover BriaCell's personalized immunotherapy and BriaPro's research on tumor-targeted checkpoint inhibitors and engineered CD80 variants. These findings aim to advance cancer treatment strategies.

Read more →
BCTX
Sep 14, 2026
BCTXPhases

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

BriaCell Therapeutics Corp. received a positive recommendation from the Data Safety Monitoring Board (DSMB) for its Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer. This marks the seventh consecutive positive review, affirming the treatment's safety and tolerability. The study is being conducted under FDA Fast Track designation, addressing significant unmet medical needs.

Read more →
BCTX
Sep 8, 2026
BCTXPhases

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell Therapeutics has expanded its pivotal Phase 3 study of Bria-IMT for metastatic breast cancer to include Memorial Sloan Kettering Cancer Center. The trial, which now has over 80 active sites, aims to evaluate the combination of Bria-IMT and an immune checkpoint inhibitor. The study has received positive feedback from the Data Safety Monitoring Board and has been recognized by Nature Medicine as a significant clinical trial.

Read more →
BCTX
Aug 24, 2026
BCTXPhases
▼ -7%on this news

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+(TM)

BriaCell Therapeutics has announced advancements in its personalized melanoma immunotherapy, Bria-MEL+. The vaccine candidate utilizes a patient's saliva to select premanufactured cell lines, eliminating the need for individualized manufacturing. This approach aims to enhance accessibility and reduce treatment costs while targeting melanoma, a significant unmet medical need. The program has recently achieved a key milestone in genetic engineering.

Read more →
BCTX
Aug 24, 2026
BCTXPhases
▼ -15%on this newsshared move

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

BriaCell Therapeutics has announced progress in its Bria-MEL+ personalized melanoma immunotherapy, achieving a key genetic engineering milestone. This off-the-shelf vaccine aims to utilize patients' immune systems without the need for individualized manufacturing. The approach is expected to enhance accessibility and reduce costs while targeting melanoma, a significant unmet medical need.

Read more →
BCTX
Aug 5, 2026
BCTXFDA Updates

BriaCell Receives FDA Clearance to Initiate Bria-PROS+(TM) Clinical Study in Prostate Cancer

BriaCell Therapeutics has received FDA clearance to begin a Phase 1/2a clinical study of Bria-PROS+, a personalized immunotherapy for prostate cancer. This innovative treatment aims to enhance immune activation and has previously secured a $2 million grant from the National Cancer Institute. The company is optimistic about its potential therapeutic benefits.

Read more →
BCTX
Aug 5, 2026
BCTXPhases

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

BriaCell Therapeutics has received FDA clearance to begin a Phase 1/2a clinical study of its personalized immunotherapy, Bria-PROS+, for prostate cancer. This innovative treatment is designed to activate multiple immune system components, potentially improving therapeutic outcomes. The program has also secured a $2 million grant from the US National Cancer Institute to support its development.

Read more →
BCTX
Jul 16, 2026
BCTXPhases

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Therapeutics has opened its first Canadian site at Sunnybrook's Odette Cancer Centre for its pivotal Phase 3 trial in metastatic breast cancer. This trial evaluates the efficacy of Bria-IMT combined with an immune checkpoint inhibitor. The study aims to improve treatment options for patients with advanced metastatic breast cancer, with a focus on overall survival as the primary endpoint.

Read more →
BCTX
Jul 15, 2026
BCTXPhases
▲ +6.5%on this newsshared move

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

BriaCell Therapeutics has secured a manufacturing arrangement with FUJIFILM Biotechnologies California to support the ongoing pivotal Phase 3 study of its lead candidate, Bria-IMT, in metastatic breast cancer. This partnership aims to ensure sufficient manufacturing capacity for both the clinical trial and future commercial needs. The collaboration is seen as a significant milestone in BriaCell's development strategy.

Read more →
BCTX
Jul 7, 2026
BCTXPhases

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Therapeutics has engaged Charles River Associates and Kaleio, Inc. to support the commercial strategy and market access evaluation for its investigational therapy, Bria-IMT, currently in a pivotal Phase 3 study for metastatic breast cancer. This step aims to prepare for potential future commercialization and strategic discussions, contingent on successful clinical development and regulatory approvals.

Read more →
BCTX
Jun 25, 2026
BCTXPhases

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

BriaCell Therapeutics has partnered with Uneedle to utilize its microneedle technology for the intradermal administration of Bria-IMT, a candidate in a Phase 3 study for metastatic breast cancer. This collaboration aims to enhance the efficiency and patient experience of drug delivery. The partnership is contingent on successful regulatory approval.

Read more →
BCTX
Jun 2, 2026
BCTXGeneral

BriaCell Therapeutics Announces Closing of Offering

BriaCell Therapeutics Corp. has announced the successful closing of its best-efforts offering, selling 1,449,300 common shares at $3.25 each, totaling around $4.7 million. The proceeds will support working capital and corporate objectives. The offering was facilitated by ThinkEquity and complies with TSX regulations for interlisted issuers.

Read more →
BCTX
Jun 1, 2026
BCTXPhases
▼ -9.1%on this newsshared move

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Corp. presented positive clinical data at the 2026 ASCO Annual Meeting, highlighting results from its Bria-IMT regimen in heavily pre-treated metastatic breast cancer patients. The final Phase 2 data revealed high survival rates, with 55% of patients surviving over one year and 27% over two years. Additionally, the TWiST analysis indicated a significant benefit regarding time without disease symptoms or toxicities. Ongoing analyses support the early quality of life and biomarker data from the ongoing Phase 3 Bria-ABC trial.

Read more →
BCTX
May 31, 2026
BCTXGeneral
▼ -12.1%on this news· ran to -23% by day 3

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Therapeutics Corp. has announced the pricing of an offering for 1,449,300 common shares at $3.25 each, aiming to raise about $4.7 million in gross proceeds. The offering is set to close on June 2, 2026, subject to customary closing conditions. The company plans to utilize the net proceeds for working capital and general corporate purposes, alongside advancing its business objectives. The offering is offered under a shelf registration statement filed with the SEC.

Read more →
BCTX
May 26, 2026
BCTXPhases

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics Corp. has received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) for its Phase 3 study of Bria-IMT combined with an immune checkpoint inhibitor in metastatic breast cancer. This marks the sixth consecutive positive recommendation, affirming the safety and tolerability of the treatment. The study is being conducted under FDA Fast Track Designation due to significant unmet medical needs in this patient population.

Read more →
BCTX
May 22, 2026
BCTXPhases
▼ -6.2%on this newsshared move

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT(TM) at ASCO 2026

BriaCell Therapeutics Corp. presented positive clinical data for Bria-IMT at the ASCO 2026 Annual Meeting. Key findings include a median overall survival of 16.6 months in Phase 2 and favorable quality of life metrics in heavily pre-treated metastatic breast cancer patients. The ongoing Phase 3 study continues to show promise in improving patient outcomes.

Read more →
BCTX
May 22, 2026
BCTXConferences/Events
▼ -6.2%on this newsshared move

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Therapeutics Corp. presented promising clinical data for Bria-IMT at the 2026 ASCO Annual Meeting. The final Phase 2 results indicated a median overall survival of 16.6 months, while quality of life metrics showed stability among heavily pre-treated metastatic breast cancer patients. Biomarker analyses from the ongoing Phase 3 study further supported the efficacy of Bria-IMT.

Read more →
BCTX
May 15, 2026
BCTXPhases
▼ -26.6%on this news

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+(TM)

BriaCell Therapeutics Corp. is expanding its pipeline to include Bria-OVA+, a personalized immunotherapy candidate for ovarian cancer. This follows successful Phase 2 results in metastatic breast cancer. The new candidate aims to provide enhanced anti-tumor activity and address significant unmet needs for ovarian cancer patients. BriaCell is actively developing Bria-OVA+ for potential clinical use.

Read more →

About BriaCell Therapeutics Corp.

West Vancouver, A1 4 employees briacell.com
Headquarters3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, A1, V7T 2X1
Founded2006
BIOPHARMAWATCH ELITE PLUS
Trade the next BCTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime